Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
House Dust Mite Allergy - Overview
House Dust Mite Allergy - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
House Dust Mite Allergy - Therapeutics Assessment
Assessment by Route of Administration
Assessment by Molecule Type
House Dust Mite Allergy - Companies Involved in Therapeutics Development
ALK-Abello AS
Allergy Therapeutics Plc
Anergis SA
ASIT Biotech SA
Astellas Pharma Inc
Biomay AG
Genetic Immunity Inc
Roxall Medizin GmbH
Stallergenes Greer plc
House Dust Mite Allergy - Drug Profiles
Allergan for Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Allergen for Allergic Asthma and House Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-2390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BM-35 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
clustoid d. pteronyssinus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DermAll-HDM - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
hdm-ASIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
house dust mite (Dermatophagoides farie) allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-103 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized mite (Dermatophagoides farie + Dermatophagoides pteronyssinus) allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
standardized mite (Dermatophagoides pteronyssinus + Dermatophagoides farie) allergen extract - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine for House Dust Mite Allergy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
House Dust Mite Allergy - Dormant Projects
House Dust Mite Allergy - Discontinued Products
House Dust Mite Allergy - Product Development Milestones
Featured News & Press Releases
Jun 03, 2019: Targeted early treatment with ALKs ACARIZAX could improve allergic asthma treatment, allergy congress hears
May 31, 2019: Stallergenes Greer will be at 2019 EAACI Congress and present the results of its phase III House Dust Mites Tablet trial
Nov 20, 2018: Stallergenes Greer announces that the phase III trial for its sublingual allergy immunotherapy tablet STAGR320 to treat house dust mite-induced allergic rhinitis achieved its primary endpoint
May 29, 2018: Allergy Therapeutics - Positive new data with house-dust mite immunotherapy
Feb 21, 2018: New medicine for house dust mite allergic rhinitis and allergic asthma now available in France
Feb 16, 2018: Shionogi Got Approval of Partial Change Application in Dosage and Administration in Japan of Actair for Allergen Immunotherapy of Pediatric Allergic Rhinitis Caused by House Dust Mites
Feb 16, 2018: Torii Receives Approval for Additiol Dosage and Administration for Pediatric Indication for MITICURE House Dust Mite Sublingual Tablets
Jan 11, 2018: New Treatment for House Dust Mite (HDM) - Induced Allergic Rhinitis Now Available in US
Nov 30, 2017: ALK secures pricing and reimbursement for ACARIZAX in France
Nov 23, 2017: European Patent Office Grants to ASIT biotech a Second Patent Related to the Active Ingredients Used in the ASIT+ Allergy Immunotherapy Product Candidates
Oct 24, 2017: ASIT biotech Publishes the Results of The hdm-ASIT+ Phase I/II Follow-up Study in House Dust Mite Rhinitis
Sep 26, 2017: Stallergenes Greer Advances Its House Dust Mite Allergy Pipeline With Acceptance Of Regulatory Submission And New Market Approval
Aug 21, 2017: ALK to accelerate launches of ODACTRA in the USA / ACARIZAX in Cada
Aug 16, 2017: ASIT biotech Announces the Approval by the Regulatory Authorities of a Follow-up Study of the Phase I/IIa Clinical Trial with its hdm-ASIT Product Candidate for House Dust Mite Rhinitis
Jul 27, 2017: Stallergenes Greer Announces Completion of Enrollment in Largest Phase III Study to Treat House Dust Mites Allergy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for House Dust Mite Allergy, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for House Dust Mite Allergy, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
House Dust Mite Allergy - Pipeline by ALK-Abello AS, H2 2019
House Dust Mite Allergy - Pipeline by Allergy Therapeutics Plc, H2 2019
House Dust Mite Allergy - Pipeline by Anergis SA, H2 2019
House Dust Mite Allergy - Pipeline by ASIT Biotech SA, H2 2019
House Dust Mite Allergy - Pipeline by Astellas Pharma Inc, H2 2019
House Dust Mite Allergy - Pipeline by Biomay AG, H2 2019
House Dust Mite Allergy - Pipeline by Genetic Immunity Inc, H2 2019
House Dust Mite Allergy - Pipeline by Roxall Medizin GmbH, H2 2019
House Dust Mite Allergy - Pipeline by Stallergenes Greer plc, H2 2019
House Dust Mite Allergy - Dormant Projects, H2 2019
House Dust Mite Allergy - Discontinued Products, H2 2019